<DOC>
	<DOCNO>NCT01706796</DOCNO>
	<brief_summary>The primary purpose study estimate relative bioavailability food effect PF-06273340 tablet .</brief_summary>
	<brief_title>A Study Comparing PF-06273340 Immediate Release Tablet , PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State . This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male and/or female subject nonchild bear potential , age 21 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month Screening . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . Screening supine blood pressure &gt; =140 mm Hg ( systolic ) &gt; =90 mm Hg ( diastolic ) , single measurement ( confirm single repeat , necessary ) follow least 5 minute rest . Evidence history orthostatic hypotension . 12lead ECG demonstrate QTc &gt; 450 QRS interval &gt; 120 msec Screening . If QTc exceed 450 msec , QRS exceed 120 msec , ECG repeat two time average three QTc value use determine subject 's eligibility . Pregnant nursing female ; female childbearing potential , include tubal ligation . Use prescription nonprescription drug , vitamin dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement must discontinue 28 day prior first dose study medication . As exception , acetaminophen/paracetamol may use dos &lt; =1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . Unwilling unable comply Lifestyle guideline describe protocol . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Subjects investigational site staff member relatives site staff member subject Pfizer employee directly involve conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Pain</keyword>
</DOC>